BioXcel Therapeutics, Inc. (BTAI) Social Stream

Featured Post From StockTwits About BTAI

$BTAI I am long and adding. Plenty of cash and a strong list of news that can come in the next 6 months. I get the frustration on the stock price but it has been on extremely low volume and a very down XBI. If the news comes as expected then the below analyst price targets could be reached.

A number of other research analysts have also weighed in on BTAI. HC Wainwright reduced their target price on BioXcel Therapeutics from $176.00 to $140.00 and set a “buy” rating for the company in a report on Monday, June 28th. Truist Securities cut their price objective on BioXcel Therapeutics from $128.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, June 23rd. Ten analysts have rated the stock with a buy rating, BioXcel Therapeutics currently has a consensus rating of “Buy” and an average price target of $102.00.

https://www.tickerreport.com/banking-finance/7766981/jefferies-financial-group-comments-on-bioxcel-therapeutics-inc-s-q3-2021-earnings-nasdaqbtai.html